TeamDrive
RUS

Russia and Bulgaria signed cooperation agreement

18 July 2018

GMP News

Last week, on July 10, 2018, in Sofia Vladislav Shestakov – Director of the State Institute of Drugs and Good Practices, Deputy Head of the State GMP Inspectorate met with Professor Assena Stoimenova, Executive Director of the Bulgarian Drug Agency (Medicines Agency of the Bulgarian Health Ministry).

The State Institute of Drugs and Good Practices and the Bulgarian Medicines Agency signed a bilateral agreement that covers professional exchanges and timely notification on anticipated inspections and critical non-compliances. The inspectorates extended invitations to the major pharmaceutical events: the first in history joint conference of Bulgarian-Cuban regulators, GxP summit for university students and postgraduates, as well as the 3rd All-Russia GMP Conference. The delegates also discussed the observers’ participation in pharmaceutical inspections, an organization of educational inspections, and joint educational programs development, supplementary education, and advanced skills projects.

“We continue to strengthen international cooperation between regulatory authorities, and by signing the present Agreement with the Bulgarian Inspectorate we made a big step towards our goal. Intensive interaction between our nations in the pharmaceutical industry fills me with great expectation: our discussion was not limited to regulatory issues only, we also talked about the future of the industry – our students,“ – said Mr. Shestakov.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more